Skip to main content
. 2018 May 29;32(3):281–291. doi: 10.1007/s40259-018-0284-3

Fig. 5.

Fig. 5

Mean value contributions of each quantitative criterion and overall value estimates for dupilumab and secukinumab. Average of the committee of experts and for each group (clinicians, decision makers and patients). Value contribution=normalised weight×normalised weight=value contribution of all13criteria. ETN etanercept, PBO placebo, UTK ustekinumab